{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 333,
  "pageCount": 415,
  "prevPage": 332,
  "nextPage": 334,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses direct quotes from a trial investigator to undermine the company's value proposition.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/333",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-333",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Trial investigator #7 stated that Vykat makes no sense versus cheap, generic diazoxide suspension, with which he and other endocrinologists already have experience using “for many years.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b3-9207679338f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.86,
        "x": 0.07,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Extensive experience with generic diazoxide; unconvinced that Vykat extended release formulation adds any value",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48de05c9-9a16-4c68-9296-577c55204c5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.86,
        "x": 0.07,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Diazoxide already has a long half-life; only need once a day dosing for older kids with liquid; generic liquid is substitutable and expects hospital to ask him to use it instead",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69a3d574-b5fa-4961-9073-7a8aadfd6ba2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "quote",
      "text": "“Diazoxide I use regularly, and I use it in babies. My other interest, as well as Prader-Willi Syndrome, is hyperinsulinism. I am familiar with diazoxide, and I have been using it for many years. I normally give 2-3 times a day, and there is a liquid preparation. There are capsules. Although the liquid preparation, which is more stable...I suppose the question — is it worth the difference? Obviously, when we participated in the trial, we weren't aware of the costs and so on. I want to know whether that drug is more effective or not. Now, whether it's the extended coding that makes a difference, whether it's diazoxide, it's probably just the diazoxide, where the extended release probably makes no difference at all. And you could argue, why give something once a day, which is great compliance-wise, and it's great for the patient. But half to $1 million is a bit excessive for something that you could do for a year, for $1,000 at most. There is that issue. Is it really going to be effective? I'm not convinced whether it's the actual choline, the extended choline release that makes a big difference, or whether, is it really just the diazoxide?” -Trial investigator, endocrinologist, key opinion leader for PWS",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f0da0d9-5880-47d6-bb2d-8bb26a5f6f84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.86,
        "x": 0.07,
        "y": 0.7
      },
      "kind": "quote",
      "text": "“I'm not a pharmacologist, so I don't know the kind of pharmacokinetics, but, if it's diazoxide and certainly when I've used it for hyperinsulinism, it does last. I know it's got a long half-life, although we routinely prescribe it 2-3 times a day, I know as a child is older — the babies need more but as a child is older, once a day and even when they come off it, it takes a week or even two weeks before you see the kind of effects of diazoxide wearing off. I know it's got a long half-life. Could we just use diazoxide instead of this very expensive Vykat? That's probably true. My management will ask, \"Well, fine. You have no other drug? Okay. We can use it.\" -Trial investigator, endocrinologist, key opinion leader for PWS",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e528ade-86f9-49ce-833d-4df02632c14d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Diazoxide I use regularly, and I use it in babies... is it worth the difference? Obviously, when we participated in the trial, we weren't aware of the costs and so on... it's probably just the diazoxide, where the extended release probably makes no difference at all... half to $1 million is a bit excessive for something that you could do for a year, for $1,000 at most.” — Trial investigator, endocrinologist, key opinion leader for PWS",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b3-94469d049dc8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26438680-e08a-4e44-aefc-1cd57af3bf2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #7 stated that Vykat makes no sense versus cheap, generic diazoxide suspension, with which he and other endocrinologists already have experience using “for many years.”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e417c03-5d4a-4fd0-9404-f4171389a2a7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}